Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

• Auriane Lesieur,
• Xavier Thomas,
• Olivier Nibourel,
• Nicolas Boissel,
• Laurène Fenwarth,
• Stéphane De Botton,
• Elise Fournier,
• Karine Celli-Lebras,
• Emmanuel Raffoux,
• Christian Recher,
• Juliette Lambert,
• Céline Berthon,
• Arnaud Pigneux,
• Raphael Itzykson,
• Pascal Turlure,
• Cécile Pautas,
• Jacques Vargaftig,
• Claude Preudhomme,
• Hervé Dombret,
• Nicolas Duployez

Affiliations

Auriane Lesieur

CHU Lille, Laboratory of Hematology, F-59000 Lille

Xavier Thomas

Hospices Civils de Lyon, Lyon-Sud University Hospital, Department of Hematology, Lyon

Olivier Nibourel

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 – UMR-S 1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille

Nicolas Boissel

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris

Laurène Fenwarth

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 – UMR-S 1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille

Stéphane De Botton

Gustave Roussy Institute, Department of Hematology, Villejuif

Elise Fournier

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 – UMR-S 1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille

Karine Celli-Lebras

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris

Emmanuel Raffoux

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris

Christian Recher

Toulouse Cancer University Institute, Department of Hematology, Toulouse

Juliette Lambert

CH Versailles, Department of Hematology, Le Chesnay

Céline Berthon

Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 – UMR-S 1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, FRANCE; CHU Lille, Department of Clinic Hematology, F-59000 Lille

Arnaud Pigneux

Bordeaux Haut-Lévêque University Hospital, Department of Hematology, Pessac

Raphael Itzykson

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris

Pascal Turlure

CHU Limoges, Univ. Limoges, Department of Hematology, Limoges

Cécile Pautas

AP-HP, Department of Hematology, Henri Mondor Hospital, Créteil

Jacques Vargaftig

Curie Hospital, René Huguenin Hospital, Saint-Cloud

Claude Preudhomme

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 – UMR-S 1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille

Hervé Dombret

AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris

Nicolas Duployez

CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 – UMR-S 1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille